Journal of substance abuse treatment
March 1, 2007
Traci Rieckmann, Marilyn Daley, Bret E Fuller et al.
75 citations
In a survey of 376 counselors and 1,083 clients from outpatient, methadone, and residential drug treatment programs, attitudes, perceived social norms, and intentions regarding four medications for opiate dependence—methadone, buprenorphine, clonidine, and ibogaine—varied by treatment setting. Methadone clients and counselors held more positive attitudes toward methadone, while those in residential and outpatient settings rated it neutrally or negatively. Buprenorphine received relatively neutral assessments across all settings. Clonidine and ibogaine were viewed negatively by both groups everywhere. Perceived social norms, particularly beliefs about peers' views, strongly influenced intentions to use medications, suggesting peer perceptions play a critical role in medication adoption for opiate dependence.
Journal of Psychopharmacology
June 18, 2024
Kim Hoffman, Alissa Bazinet, Kellie Pertl et al.
14 citations
Experts with extensive experience facilitating psilocybin experiences, including in ceremonial settings, indigenous practices, and clinical trials, developed a set of core measures to monitor the safety, quality, and outcomes of supervised psilocybin services. Through a three-phase e-Delphi process with 36 experts, 55 candidate measures were identified and then prioritized to a core set of 11 process measures (e.g., preparatory hours with client, documentation of touch/sexual boundaries), 11 outcome measures (e.g., adverse events, well-being), and 17 structure measures (e.g., facilitator training in trauma informed care). The findings suggest that service providers and policy makers should consider standardizing these measures for community-based psilocybin services.
Journal of Psychoactive Drugs
September 13, 2024
Ar Wilson-Poe, Ka Hoffman, Jb Luoma et al.
9 citations
Experts with a mean of 15.2 years of experience facilitating psilocybin experiences overwhelmingly view first-hand experience with psychedelics as important for facilitators in emerging state-legal frameworks. Personal experience may indirectly improve care quality by enhancing facilitators' wellbeing and helping them understand clients' experiences. One participant questioned this necessity. The current legal frameworks in Oregon and Colorado do not address facilitators' personal psychedelic experience, creating an opportunity to study its association with service safety and outcomes.
Journal of Psychoactive Drugs
January 29, 2025
Jason B Luoma, Kim Hoffman, Adrianne R Wilson-Poe et al.
3 citations
Oregon's early psilocybin facilitator workforce is relatively diverse, with many holding existing healthcare licenses. Among 16 active training programs, mean tuition was $9,359 and half offered diversity scholarships. Survey respondents (n=106) reported that training expenses were a moderate-to-severe financial strain, though most were satisfied with their training. The mean planned price for a session was $1,388, and common specializations included trauma, mental disorders, consciousness exploration, and spirituality. Facilitators requested ongoing training opportunities. These findings are crucial for informing future policy and training program development to support a diverse and effective workforce.
March 11, 2026
Jason B Luoma, Kim Hoffman, Adie Wilson-Poe et al.
preprint
Oregon's early psilocybin facilitator workforce is relatively diverse, with many holding existing healthcare licenses, though training expenses pose a moderate-to-severe financial strain for most. The mean tuition across 16 active training programs was $9,359, half offered diversity scholarships, and the mean planned session price was $1,388. Facilitators most commonly specialized in trauma, mental disorders, consciousness exploration, and spirituality, and most were satisfied with training while requesting ongoing opportunities. These findings inform future policy and program development for a diverse and effective workforce.